2024-07-09 13:48:29 ET
Summary
- uniQure reported positive interim results across phase 1/2 studies, using AMT-130 for the treatment of patients with Huntington's Disease, leading to an 80% slowing of disease progression.
- The company plans to meet with the FDA in H2 2024 to discuss the possible Accelerated Approval pathway of AMT-130 for the treatment of patients with Huntington's Disease.
- 36-month data from the phase 1/2 studies using AMT-130 for the treatment of patients with Huntington's Disease is expected in mid-2025.
- The global Huntington's Disease market is projected to reach $1.21 billion by 2032.
uniQure N.V. ( QURE ) just recently reported results from its phase 1/2 study using AMT-130 for the treatment of patients with Huntington's Disease [HD]. This was interim 24-month data that showed patients given this gene therapy were able to show an 80% slowing of disease progression compared to external control with respect to a highly important rating scale used to measure disease. This positive interim data caused the stock price to trade higher by 50% premarket. If this catalyst was just released, then why should investors still consider an investment opportunity here? Aside from the fact that it still has a market cap of only around $200 million, the newly released results from this phase 1/2 study leads to several other catalysts for investors to look forward to....
Read the full article on Seeking Alpha
For further details see:
uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts